Media.Player

Fluorescent Labeled Lipase Inhibitors

详细技术说明

None

*Abstract

Ref: 14UMS004DETECTING & TREATING TB USING LIPASE INHIBITORSTuberculosis continues to kill nearly 1.5 million people annually, making it the most deadly infectious diseaseworldwide especially in Sub-Saharan Africa, Russia and Eastern Europe. With the recent emergence of multipledrug-resistant strains together with the increasing number of HIV cases, as well as the disappointing failures of theGates-backed TB vaccine (MV85A), the need for novel therapeutic approaches is more pressing than ever.While there is growing awareness of the need for diagnosing tuberculosis and drugs that can treat the disease, manyof the promising new molecules in development are either repurposed drug compounds or new derivatives of knownanti-mycobacterial drugs and none are reported to target intracellular lipid metabolism.Researchers at the University of Missouri St. Louis, in collaboration with scientists at the National Center forScientific Research (CNRS) in France, have developed powerful lipase inhibitors from enolphosphonate andenolphosphate families that show promising anti-tuberculous activities on M. tb with no cytotoxicity effects.Additionally, fluorescently labeled compounds were shown to easily identify mycobacterial proteins that react withthe inhibitors.Selective inhibition of lipolytic enzymes (both extracellular and intracellular) from M. tb by this new class ofenolphosphonates may be used to develop more selective anti-microbial agents, and, more specifically,anti-mycobacterial compounds.Development Status: US National StageCONTACTTo discuss this opportunity, please email:Craig WeilbaecherLicensing & Business Development AssociateUniversity of Missouri-St. Louisweilbaecherc@umsl.edu314-516-4248

*Principal Investigation

Name: Christopher Spilling

Department:

Name: Benjamin Martin, Graduate, Chemistry

Department:

Name: Jean-Francois Cavalier

Department:

Name: Stephane Canaan

Department:

其他

国家/地区

美国